-
Something wrong with this record ?
Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs
J. Fadraersada, R. Alva-Gallegos, P. Skořepa, F. Musil, L. Javorská, K. Matoušová, LK. Krčmová, M. Paclíková, A. Carazo, V. Blaha, P. Mladěnka
Language English Country Germany
Document type Journal Article, Comparative Study, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2013-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2013-01-01 to 1 year ago
- MeSH
- Anticoagulants * pharmacology MeSH
- Arginine * analogs & derivatives MeSH
- Dabigatran pharmacology MeSH
- Adult MeSH
- Blood Coagulation * drug effects MeSH
- Body Mass Index MeSH
- International Normalized Ratio MeSH
- Pipecolic Acids * pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Partial Thromboplastin Time MeSH
- Prothrombin Time MeSH
- Cross-Sectional Studies MeSH
- Pyrazoles pharmacology MeSH
- Pyridones pharmacology pharmacokinetics MeSH
- Rivaroxaban * pharmacology MeSH
- Sulfonamides pharmacology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
An imbalance in coagulation is associated with cardiovascular events. For prevention and treatment, anticoagulants, currently mainly xabans and gatrans, are used. The purpose of the present study was to provide a head-to-head comparison since there are no studies directly evaluating these novel anticoagulants. An additional aim was to find whether selected anthropological and biochemical factors can affect their anticoagulant properties as they are used in fixed doses. In this cross-sectional study, blood from 50 generally healthy donors was collected, and coagulation responses to dabigatran, argatroban, rivaroxaban, and apixaban, at a concentration of 1 μM, were analyzed. Heparin was used as a positive control. Prothrombin time (PT) expressed as international normalized ratio (INR) and activated partial thromboplastin time (aPTT) were measured and compared. Rivaroxaban was the most active according to PT/INR while argatroban according to aPTT. The ex vivo anticoagulant effect measured by INR correlated inversely with body mass index (BMI) in all four anticoagulants tested. Shortening of aPTT was associated with higher cholesterol and triglyceride levels. No sex-related differences were observed in response to the anticoagulant treatments. As this was an ex vivo study and pharmacokinetic factors were not included, the influence of BMI is of high therapeutic importance.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013807
- 003
- CZ-PrNML
- 005
- 20240905133521.0
- 007
- ta
- 008
- 240725s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00210-023-02891-x $2 doi
- 035 __
- $a (PubMed)38112731
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Fadraersada, Jaka $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 245 10
- $a Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs / $c J. Fadraersada, R. Alva-Gallegos, P. Skořepa, F. Musil, L. Javorská, K. Matoušová, LK. Krčmová, M. Paclíková, A. Carazo, V. Blaha, P. Mladěnka
- 520 9_
- $a An imbalance in coagulation is associated with cardiovascular events. For prevention and treatment, anticoagulants, currently mainly xabans and gatrans, are used. The purpose of the present study was to provide a head-to-head comparison since there are no studies directly evaluating these novel anticoagulants. An additional aim was to find whether selected anthropological and biochemical factors can affect their anticoagulant properties as they are used in fixed doses. In this cross-sectional study, blood from 50 generally healthy donors was collected, and coagulation responses to dabigatran, argatroban, rivaroxaban, and apixaban, at a concentration of 1 μM, were analyzed. Heparin was used as a positive control. Prothrombin time (PT) expressed as international normalized ratio (INR) and activated partial thromboplastin time (aPTT) were measured and compared. Rivaroxaban was the most active according to PT/INR while argatroban according to aPTT. The ex vivo anticoagulant effect measured by INR correlated inversely with body mass index (BMI) in all four anticoagulants tested. Shortening of aPTT was associated with higher cholesterol and triglyceride levels. No sex-related differences were observed in response to the anticoagulant treatments. As this was an ex vivo study and pharmacokinetic factors were not included, the influence of BMI is of high therapeutic importance.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a antikoagulancia $x farmakologie $7 D000925
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a arginin $x analogy a deriváty $7 D001120
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a rivaroxaban $x farmakologie $7 D000069552
- 650 _2
- $a parciální tromboplastinový čas $7 D010314
- 650 12
- $a kyseliny pipekolové $x farmakologie $7 D010875
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a hemokoagulace $x účinky léků $7 D001777
- 650 _2
- $a pyrazoly $x farmakologie $7 D011720
- 650 _2
- $a protrombinový čas $7 D011517
- 650 _2
- $a dabigatran $x farmakologie $7 D000069604
- 650 _2
- $a pyridony $x farmakologie $x farmakokinetika $7 D011728
- 650 _2
- $a sulfonamidy $x farmakologie $7 D013449
- 650 _2
- $a INR $7 D019934
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Alva-Gallegos, Raúl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Skořepa, Pavel $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic $u Department of Military Internal Medicine and Military Hygiene, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
- 700 1_
- $a Musil, František $u Department of Occupational Medicine, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Javorská, Lenka $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Matoušová, Kateřina $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Krčmová, Lenka Kujovská $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Paclíková, Markéta $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Carazo, Alejandro $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Blaha, Vladimír $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Mladěnka, Přemysl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic. mladenkap@faf.cuni.cz
- 773 0_
- $w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 397, č. 6 (2024), s. 4461-4470
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38112731 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133515 $b ABA008
- 999 __
- $a ok $b bmc $g 2143552 $s 1225673
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 397 $c 6 $d 4461-4470 $e 20231219 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
- LZP __
- $a Pubmed-20240725
